AI-powered CKD drug ISM4808 licensed for kidney disease therapy
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license…
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.




